Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 4/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11738816 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2FPR2KMT2AALDH1A1LMNA | |
| SCHEMBL11739171 | 0.81 | CA12 (0.34) | SMN1; SMN2ALDH1A1HSD17B10HTT | |
| Hydrochloric Acid SCHEMBL3589853 | 0.81 | SMN1; SMN2 (0.42) | SMN1; SMN2FPR2KMT2ALMNA | |
| SCHEMBL2960305 | 0.77 | ALPL (0.50) | SMN1; SMN2GAAKMT2AKDM4EALDH1A1 | |
| SCHEMBL13010096 | 0.76 | TLR8 (0.45) | SMN1; SMN2GAAFPR2KMT2AKDM4E | |
| SCHEMBL13072246 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2GAAFPR2KMT2AKDM4E | |
| SCHEMBL14889017 | 0.74 | MAPT (0.37) | SMN1; SMN2KMT2AALDH1A1POLB | |
| SCHEMBL3582565 | 0.74 | FPR2 (0.43) | SMN1; SMN2GAAFPR2KMT2AKDM4E | |
| SCHEMBL568442 | 0.74 | KMT2A (0.36) | KMT2AALDH1A1POLBDYRK1A | |
| SCHEMBL3589998 | 0.74 | GAA (0.40) | SMN1; SMN2GAAATMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | SMN1; SMN2 4711/4885GAA 4433/4885FPR2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.